The immunosuppressant fingolimod ameliorates experimental autoimmune myasthenia gravis by regulating T-cell balance and cytokine secretion.

Luo, Ya-Ting; Liang, Ying-Fan; He, Huan; Zhang, Meng-Ting; Wang, Rui; Li, Hong-Lin

Luo, Ya-Ting; Liang, Ying-Fan; He, Huan; Zhang, Meng-Ting; Wang, Rui; Li, Hong-Lin.

Afiliación

Luo YT; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology 130 Meilong Road, Shanghai, PR China.
Liang YF; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology 130 Meilong Road, Shanghai, PR China.
He H; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology 130 Meilong Road, Shanghai, PR China.
Zhang MT; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology 130 Meilong Road, Shanghai, PR China.
Wang R; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology 130 Meilong Road, Shanghai, PR China.
Li HL; Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology 130 Meilong Road, Shanghai, PR China.

Am J Transl Res ; 12(6): 2600-2613, 2020.

Article en En | MEDLINE | ID: mdl-32655793

Palabras clave

Myasthenia gravis; Th cells; cytokines; fingolimod; lymphocyte proliferation

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Am J Transl Res Año: 2020 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google